000			03385nam a22004577a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a1878-0938
024			_aS1553-8389(24)00496-2 [pii]
040			_aOvid MEDLINE(R)
099			_a38845281
245			_aDrug-coated balloons for coronary artery disease: An updated review with future perspectives. [Review]
251			_aCardiovascular Revascularization Medicine. 2024 May 23
252			_aCardiovasc Revasc Med. 2024 May 23
253			_aCardiovascular revascularization medicine : including molecular interventions
260			_c2024
260			_fFY2024
260			_p2024 May 23
265			_saheadofprint
265			_tPublisher
266			_d2024-08-07
266			_z2024/06/07 02:06
501			_aAvailable in print through MWHC library: 2002 - present
520			_aSince the advent of coronary stents, two of the most common long-term complications after percutaneous coronary intervention (PCI) are in-stent restenosis (ISR) and stent thrombosis (ST). Although the rates of ST have been nearly abolished and ISR rates have declined with the current gold-standard second-generation drug-eluting stents (DES), late ISR of DES remains a valid concern in the field of interventional cardiology. The drug-coated balloon (DCB) is a non-stent technology that relies on the concept of targeted homogeneous drug delivery from an inflated balloon to restore luminal vascularity, treat atherosclerosis, and overcome some limitations of PCI, including ISR and prolonged dual antiplatelet therapy to prevent ST by leaving nothing behind. Most clinical evidence on coronary DCBs predominantly comes from small, randomized data and registries using paclitaxel DCBs for ISR and de novo lesions in the coronary space. Since 2014, outside the United States, DCBs have been approved for the treatment of ISR, with a class I recommendation by the European Society of Cardiology. The Food and Drug Administration very recently approved the Agent DCB to treat ISR in patients with coronary artery disease in the US. Additionally, recent randomized clinical data also showed DCB's safety and efficacy for the treatment of de novo small-vessel disease and high-bleeding-risk patients, while their role for other clinical situations including acute coronary syndrome, large-vessel disease, bifurcation lesions, and long-diffuse distal lesions is currently under investigation. Herein, we review the evidence-based role of DCBs in the treatment of coronary lesions and offer future perspectives. Copyright © 2024. Published by Elsevier Inc.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
650			_zAutomated
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aCardiovascular Disease Fellowship
657			_aJournal Article
657			_aReview
700			_aBen-Dor, Itsik _bMHVI
700			_aBhogal, Sukhdeep _bMHVI
700			_aHill, Andrew _bMWHC _cCardiovascular Disease Fellowship _dMD
700			_aMerdler, Ilan _bMHVI
700			_aWaksman, Ron _bMHVI
700			_aWermers, Jason P _bMHVI
790			_aBhogal S, Hill AP, Merdler I, Wermers JP, Ben-Dor I, Waksman R
856			_uhttps://dx.doi.org/10.1016/j.carrev.2024.05.027 _zhttps://dx.doi.org/10.1016/j.carrev.2024.05.027
942			_cART _dArticle
999			_c14400 _d14400